Congress boosts cancer research funding by 25% annually through 2030
H.R. 3873 — KO Cancer Act · Filed by Brian Fitzpatrick (R-PA) · 6 cosponsors · Introduced Jun 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The KO Cancer Act increases annual funding to the National Cancer Institute by 25% for fiscal years 2026–2030 (approximately $2.5–3 billion over five years) to accelerate cancer research and treatment innovation. It also directs the FDA and HHS to study why cancer drugs are in short supply—examining regulatory delays, manufacturing problems, and lack of generic alternatives—and report recommendations to Congress within one year. The bill benefits cancer patients, researchers, and pharmaceutical companies developing oncology treatments.
Why we flagged it
The bill's primary functional purpose is to increase National Cancer Institute appropriations by 25% annually (2026–2030) and mandate an HHS/FDA study on cancer drug shortages. It is straightforward public-health legislation with no hidden agendas or narrow carve-outs.
What the text implies
- A 25% annual increase to NCI (approximately $2.5–3 billion over five years based on 2022 baseline) may crowd out other NIH institutes' funding if not offset by broader appropriations increases, potentially affecting research into other diseases.
- The drug-shortage study may surface supply-chain vulnerabilities or regulatory bottlenecks that could prompt future legislation tightening FDA approval timelines or loosening manufacturing standards, with unintended consequences for drug safety oversight.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (cancer drug developers); biotechnology firms (oncology-focused); contract research organizations (CROs)